Canada · Delayed Price · Currency is CAD HLS Therapeutics Company Description
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally.
The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.
It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests.
In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products.
HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
| Country | Canada |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 85 |
| CEO | Craig Millian |
Contact Details
Address: 10 Carlson Court Etobicoke, ON ON Canada | |
| Phone | 647-495-9000 |
Stock Details
| Ticker Symbol | HLS |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA40390B1094 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig Stuart Millian M.B.A. | Chief Executive Officer and Director |
| John Hanna CPA, CGA, M.B.A. | Chief Financial Officer and Non-Independent Director |
| Dr. Jason A. Gross Pharm.D. | Vice President of Scientific Affairs |
| Ryan C. Lennox B.A., J.D. | Senior Vice President of Legal, Human Resources and Compliance and Corporate Secretary |
| Brian T. Walsh | Chief Commercial Officer |
| Dave Mason | Investor Relations Officer |
| David Spence | Vice President and Corporate Controller |